Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen has revealed mixed CELIA Phase II trial data for diranersen at AAIC 2026. The lowest 60 mg dose slowed clinical decline more than either 115 mg arm, although CELIA aimed to show greater benefit at higher doses. Consequently, the
  • News
Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk

Biogen has reported detailed results from the Phase 2 CELIA trial for diranersen (BIIB080) in early Alzheimer’s disease. The drug reduced tau and slowed cognitive decline across several measures. However, the lowest dose produced the strongest effect, so the study
  • News
Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk

Rechallenge in Pharmacovigilance in 2026: Causality Assessment and Drug Safety

This article explains how positive and negative drug rechallenge findings strengthen causality assessment, improve Individual Case Safety Report documentation, and support regulatory decision-making under WHO-UMC, Naranjo, EMA GVP Module VI, and ICH E2D frameworks worldwide.
  • Blog, Quality Management System
Drug safety specialist reviewing positive and negative rechallenge outcomes, adverse drug reaction data, and Individual Case Safety Report documentation.

Functional Unblinding Threatens Psychedelic Trial Credibility; FDA Guidance Could Force Phase III Redesigns

The US Food and Drug Administration (FDA) has finalized its guidance for clinical trials involving psychedelic drugs. The document covers trial design, participant safety, abuse potential, data collection, and preclinical work. The FDA and the Department of Health and Human
  • News
Functional Unblinding Threatens Psychedelic Trial Credibility; FDA Guidance Could Force Phase III Redesigns

Redi Health Reaches 9 of Top 10 Pharma Manufacturers; GxP Questions Follow

Nine of the world’s top 10 pharmaceutical manufacturers now use Redi Health to modernize patient support, according to a sponsored report published on July 13, 2026. The shift reflects demand for faster, more personalized patient experiences. However, it also places
  • News
Redi Health Reaches 9 of Top 10 Pharma Manufacturers; GxP Questions Follow

Dechallenge in Pharmacovigilance in 2026: Causality Assessment and Safety Signal Review

Explore how dechallenge in pharmacovigilance supports causality assessment, safety signal review, and regulatory reporting. Learn how positive dechallenge, negative dechallenge, and rechallenge findings help pharmaceutical teams evaluate adverse drug reactions and improve Individual Case Safety Reports.
  • Blog, Quality Management System
Pharmacovigilance causality assessment workflow showing adverse drug reaction evaluation, dechallenge outcomes, and Individual Case Safety Report review

FDA Rejected Utebzi; Now Spero Strikes a $1.1B Innovent Deal

Spero Therapeutics is shifting from antibiotics to immune and inflammatory diseases through a licensing agreement with Innovent Biologics worth up to $1.1 billion. The company will develop SP001, a CD40L antibody, outside China. At the same time, Spero secured $105
  • News
FDA Rejected Utebzi; Now Spero Strikes a $1.1B Innovent Deal

Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma

Emerging Biotech Hubs across North America, Europe, and Asia are attracting new pharmaceutical investments, research facilities, and global talent in 2026. While this expansion reflects strong industry growth, it also introduces new GMP Compliance challenges, validation demands, and Quality Systems
  • News
Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma

Good Manufacturing Practice in UK in 2026: MHRA GMP Inspection Guide

Learn how good manufacturing practice in UK supports successful MHRA inspections through risk-based quality systems, data integrity, validation, and effective CAPA. Discover the latest UK GMP expectations and practical strategies to improve inspection readiness and long-term regulatory compliance.
  • Blog, Quality Management System
Pharmaceutical manufacturing UK facility prepared for MHRA GMP inspection with cleanroom operations, quality management, and GMP compliance controls.

FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
  • News
FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track